cro.directory
← Compare landing

Accelevir vs ICON plc

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/accelevirdx/iconplc

CategoryAccelevirICON plc
Listed sitecrocro
SummaryCLIA-certified CRO specializing in ultra-sensitive molecular analytics, custom immunology assays, and integrated virology-immunology workflows for cell therapies, gene editing, and infectious disease programs.ICON is a world-leading clinical research organization providing outsourced services across the full clinical trial lifecycle, from early phase through commercialization, to pharmaceutical, biotechnology, and medical device companies.
Services
  • Virology Services
  • Immunology & Inflammation Services
  • Flow Cytometry Services
  • Genomics & Sequencing Services
  • Biomarker Assays
  • Translational Research
  • Clinical Trial Services
  • Central Laboratory Services
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Phase IV / Post-Marketing
  • Clinical Operations
  • Clinical Trial Services
  • Clinical Imaging Core Lab
  • Central Laboratory Services
  • Data Management & eClinical
  • Biostatistics & Statistical Programming
  • Medical Writing
  • Pharmacovigilance & Drug Safety
  • Regulatory Affairs
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Flow Cytometry Services
  • Bioanalysis
  • Translational Research
  • Biomarker Assays
  • Immunogenicity Assays (ADA / NAb)
  • Ligand-Binding Bioanalysis (Large Molecule)
  • LC-MS Bioanalysis (Small Molecule)
  • Cardiovascular & Metabolic Specialty Services
  • CNS Specialty Services
  • Oncology Specialty Services
  • Immunology & Inflammation Services
  • Companion Diagnostics Development
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
Modalities
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
  • Vaccine
Indications
  • Oncology
  • Immunology
  • Infectious Disease
  • Cardiovascular
  • Neurology
  • Immunology
  • Oncology
  • Infectious Disease
  • Metabolic
  • Rare Disease
  • Women's Health
  • Ophthalmology
Locations
  • Headquarters, Maryland, Maryland, United States
  • Headquarters, Dublin, Ireland
  • Belgium, Belgium, Belgium
  • Bulgaria, Bulgaria, Bulgaria
  • Germany, Germany, Germany
  • Hungary, Hungary, Hungary
  • Italy, Italy, Italy
  • Netherlands, Netherlands, Netherlands
  • Poland, Poland, Poland
  • Romania, Romania, Romania
  • Slovakia, Slovakia, Slovakia
  • South Africa, South Africa, South Africa
  • Spain, Spain, Spain
  • Türkiye, Türkiye, Türkiye
  • United Kingdom, United Kingdom, United Kingdom
  • Australia, Australia, Australia
  • China, China, China
  • India, India, India
  • Japan, Japan, Japan
  • Korea, Korea, Korea
  • Malaysia, Malaysia, Malaysia
  • Taiwan, Taiwan, Taiwan
  • Argentina, Argentina, Argentina
  • Brazil, Brazil, Brazil
  • Chile, Chile, Chile
  • Colombia, Colombia, Colombia
  • Mexico, Mexico, Mexico
  • Belgium, Belgium, Belgium
  • Bulgaria, Bulgaria, Bulgaria
  • Germany, Germany, Germany
  • Hungary, Hungary, Hungary
  • Italy, Italy, Italy
  • Netherlands, Netherlands, Netherlands
  • Poland, Poland, Poland
  • Romania, Romania, Romania
  • Slovakia, Slovakia, Slovakia
  • South Africa, South Africa, South Africa
  • Spain, Spain, Spain
  • Türkiye, Türkiye, Türkiye
  • United Kingdom, United Kingdom, United Kingdom
  • Australia, Australia, Australia
  • China, China, China
  • India, India, India
  • Japan, Japan, Japan
  • Korea, Korea, Korea
  • Malaysia, Malaysia, Malaysia
  • Taiwan, Taiwan, Taiwan
  • Argentina, Argentina, Argentina
  • Brazil, Brazil, Brazil
  • Chile, Chile, Chile
  • Colombia, Colombia, Colombia
  • Mexico, Mexico, Mexico
  • United States, United States, United States
Certifications
  • CLIA · Identifier: CLIA-certified
Data not yet provided.
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.